Armistice Capital’s Dermata Therapeutics Warrant DRMAW Stock Holding History

Armistice Capital’s Portfolio DRMAW Stock Details DRMAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,354	Closed	-$14	–	244
2024 Q4	$14	Buy	+1,354	New	+$14	﹤0.01%	230
2024 Q2	–	Sell	-20,312	Closed	-$193	–	293
2024 Q1	$193	Sell	20,312 -304,688	-94%	-$4.69K	﹤0.01%	335
2023 Q4	$142	Buy	325,000 +304,687	+1,500%	+$4.72K	﹤0.01%	292
2023 Q3	$355	Hold	20,313	–	–	﹤0.01%	252
2023 Q2	$508	Sell	20,313 -1	-0%	–	﹤0.01%	219
2023 Q1	$1.01K	Sell	20,314 -304,686	-94%	-$10.8K	﹤0.01%	225
2022 Q4	$4.75K	Hold	325,000	–	–	﹤0.01%	192
2022 Q3	$31K	Hold	325,000	–	–	﹤0.01%	192
2022 Q2	$36	Hold	325,000	–	–	﹤0.01%	173
2022 Q1	$52K	Hold	325,000	–	–	﹤0.01%	139
2021 Q4	$140K	Hold	325,000	–	–	﹤0.01%	143
2021 Q3	$270K	Buy	+325,000	New	+$334K	﹤0.01%	134

Other funds holding DRMAW

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Armistice Capital's DRMAW Position: Q1 2025 in Review

Armistice Capital sold out of Dermata Therapeutics Warrant (DRMAW) in Q1 2025, closing a stake of 1,354 shares — an estimated $14 sold.

Armistice Capital first reported a position in DRMAW in Q3 2021 and held it in 12 quarters. The position peaked at $270K in Q3 2021. 3 funds tracked by Wall St. Rank hold DRMAW as of Q1 2025.

Armistice Capital reported no remaining Dermata Therapeutics Warrant position as of Q1 2025 after selling out during the quarter.
Armistice Capital sold 1,354 Dermata Therapeutics Warrant shares in Q1 2025, an estimated $14.
Armistice Capital first reported a position in Dermata Therapeutics Warrant in Q3 2021 and held it in 12 quarters.
Armistice Capital's Dermata Therapeutics Warrant position peaked at $270K in Q3 2021.
3 funds tracked by Wall St. Rank held Dermata Therapeutics Warrant as of Q1 2025.

Based on Armistice Capital's 13F filing for Q1 2025, filed 15 May 2025.